A personalized vaccine for patients with glioblastoma produced a safe and effective immune response, according to a study published May 12 in Nature Cancer.
A phase 1 clinical trial of the vaccine was conducted at St. Louis-based Siteman Cancer Center and co-led by researchers from St. Louis-based Washington University School of Medicine and Somerville, Mass.-based Mass General Brigham.
Here are three notes on the study:
- The vaccine uses engineered DNA molecules to activate the immune system to seek out and eliminate up to 40 cancer proteins unique to each patient’s tumor, a May 12 news release from WashU Medicine said.
- Glioblastoma tumors hide from the immune system, making them harder to treat. The vaccine was able to transform the tumors, making them more susceptible to eradication, the release said.
- Of the nine adult patients enrolled in the trial, two-thirds had no cancer progression six months after surgery, two-thirds survived one year and one-third survived two years.
One patient is alive and remains cancer free today, about five years since her diagnosis.
Read the full study here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
